8-K filed Nov 13, 2026 at 21:47 ET
Vir Biotechnology priced an underwritten public offering of 15,000,000 shares of common stock at $10.00 per share, with gross proceeds of $150 million and expected net proceeds of approximately $140.4 million ($161.5 million if the underwriters' 30-day option for an additional 2,250,000 shares is fully exercised). The offering follows a recent activist stake reduction and a preliminary prospectus supplement filed one day earlier, and proceeds will fund pre-commercial activities for the CHD program, TCE oncology platform investments, and general corporate purposes. The 8.8% dilution (based on 171.3M shares outstanding) is a material negative event for existing shareholders.